Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), announced that it has received a report, prepared by Hideki Hasegawa, M.D. Ph.D., Director, Laboratory of Infectious Disease Pathology, National Institute of Infectious Disease (NIID, formerly Japan's National Institute of Health), that summarizes the results of a three (3) year Japanese government funded program to develop and test a nasally delivered H5N1 (Avian Flu) vaccine which, when coupled with Ampligen®, an experimental therapeutic, provided a robust and long lasting immune response to the vaccine. The report, entitled "Research on Clinical Applications of Influenza Vaccines Formulated for Nasal Mucosal Delivery" was filed with Japan's Ministry of Health, Labor and Welfare (MHLW), which fully funded this work in non-human primates. All reports under grants from MHLW are submitted first to MHLW and then forwarded to the National Diet Library to be made available for public review.
The path to a better tuberculosis vaccine runs through Montana